中药及天然产物改善子宫内膜异位症的作用机制

doi:10.12280/gjfckx.20240953

摘要/Abstract

摘要：

子宫内膜异位症（endometriosis，EMs）是一种育龄期最常见的良性妇科疾病之一，主要导致慢性盆腔疼痛和生育障碍。EMs病因多变、病机复杂，目前研究人员已经提出几种学说描述其发病机制，免疫和炎症也参与其中。尽管治疗EMs的传统方式已被证明有效，但也显示出严重的不良反应。中药及其天然产物在诸多医学领域里显示出独特的治疗潜力。因此，如何使用中药及其天然产物治疗EMs越来越受到关注。鉴于此，以EMs的多种病理途径为切入点，旨在探讨中药及其天然产物的作用机制，为临床应用和药物开发提供参考。

关键词: 子宫内膜异位症, 中药, 中草药, 方剂, 治疗, 天然产物

Abstract:

Endometriosis (EMs) is one of the most common benign gynecological diseases in reproductive age, leading to chronic pelvic pain and fertility disorders. The etiology of EMs is variable and complex, and several theories have been proposed to describe its pathogenesis, with immunity and inflammation involved. Although traditional modalities for treatment of EMs have proven effective, they have also shown serious adverse effects. Traditional Chinese medicine (TCM) and its natural products have shown unique therapeutic potential in many areas of medicine. Therefore, there is a growing interest in how to use herbal medicines and its natural products for the treatment of EMs. In view of this, taking the multiple pathological pathways of EMs as entry point, we aim to explore the mechanism of TCM and its natural products to provide reference for clinical application and drug development.

Key words: Endometriosis, Traditional Chinese drugs, Drugs, Chinese herbal, Chinese medical formula, Therapy, Natural products

石百超, 王宇, 常惠, 卢凤娟, 关木馨, 余健楠, 吴效科. 中药及天然产物改善子宫内膜异位症的作用机制[J]. 国际妇产科学杂志, 2025, 52(1): 66-71.

SHI Bai-chao, WANG Yu, CHANG Hui, LU Feng-juan, GUAN Mu-xin, YU Jian-nan, WU Xiao-ke. Mechanism of Traditional Chinese Medicine and Natural Products in Improving Endometriosis[J]. Journal of International Obstetrics and Gynecology, 2025, 52(1): 66-71.

参考文献 42

[1]	Lamceva J, Uljanovs R, Strumfa I. The Main Theories on the Pathogenesis of Endometriosis[J]. Int J Mol Sci, 2023, 24(5):4254. doi: 10.3390/ijms24054254.
[2]	Abramiuk M, Grywalska E, Małkowska P, et al. The Role of the Immune System in the Development of Endometriosis[J]. Cells, 2022, 11(13):2028. doi: 10.3390/cells11132028.
[3]	Rahmioglu N, Mortlock S, Ghiasi M, et al. The genetic basis of endometriosis and comorbidity with other pain and inflammatory conditions[J]. Nat Genet, 2023, 55(3):423-436. doi: 10.1038/s41588-023-01323-z. pmid: 36914876
[4]	Shi J, Tan X, Feng G, et al. Research advances in drug therapy of endometriosis[J]. Front Pharmacol, 2023,14:1199010. doi: 10.3389/fphar.2023.1199010.
[5]	Wang X, Shi Y, Xu L, et al. Traditional Chinese medicine prescription Guizhi Fuling Pills in the treatment of endometriosis[J]. Int J Med Sci, 2021, 18(11):2401-2408. doi: 10.7150/ijms.55789. pmid: 33967618
[6]	Wu Y, Zhu Y, Xie N, et al. A network pharmacology approach to explore active compounds and pharmacological mechanisms of a patented Chinese herbal medicine in the treatment of endometriosis[J]. PLoS One, 2022, 17(2):e0263614. doi: 10.1371/journal.pone.0263614.
[7]	Bo C, Wang Y. Angiogenesis signaling in endometriosis: Molecules, diagnosis and treatment (Review)[J]. Mol Med Rep, 2024, 29(3):43. doi: 10.3892/mmr.2024.13167.
[8]	You Y, Stelzl P, Joseph DN, et al. TNF-α Regulated Endometrial Stroma Secretome Promotes Trophoblast Invasion[J]. Front Immunol, 2021,12:737401. doi: 10.3389/fimmu.2021.737401.
[9]	Machairiotis N, Vasilakaki S, Thomakos N. Inflammatory Mediators and Pain in Endometriosis: A Systematic Review[J]. Biomedicines, 2021, 9(1):54. doi: 10.3390/biomedicines9010054.
[10]	申亚辉, 马艳华. 子宫内膜异位症病因和相关信号通路的研究进展[J]. 中国计划生育和妇产科, 2024, 16(5):30-34,38. doi: 10.3969/j.issn.1674-4020.2024.05.06.
[11]	朱小琳, 胡晓萌, 杨东霞, 等. 内异止痛方诊治子宫内膜异位症及Wnt/β-联蛋白信号通路调控研究[J]. 世界中医药, 2023, 18(23):3348-3352. doi: 10.3969/j.issn.1673-7202.2023.23.006.
[12]	刘瑜, 张利英, 郝国雄, 等. 缺氧诱导因子-1α在肿瘤中的病理机制及中药干预的研究现状[J]. 中国临床药理学杂志, 2024, 40(11):1670-1674. doi: 10.13699/j.cnki.1001-6821.2024.11.028.
[13]	吴李征, 陈晓鑫, 孙博文, 等. 罗氏内异方调控缺氧干预子宫内膜异位症SF-1的机制研究[J]. 中国中药杂志, 2024, 49(18):4967-4976. doi: 10.19540/j.cnki.cjcmm.20240531.401.
[14]	Lu C, Zhao H, Liu Y, et al. Novel Role of the SIRT1 in Endocrine and Metabolic Diseases[J]. Int J Biol Sci, 2023, 19(2):484-501. doi: 10.7150/ijbs.78654. pmid: 36632457
[15]	孟鑫, 付欣平, 安铭立, 等. 补肾温阳化瘀方调节SIRT1-FoxO1介导的细胞自噬治疗子宫内膜异位症的机制研究[J]. 中华中医药杂志, 2024, 39(5):2542-2548.
[16]	Zhang M, Xu T, Tong D, et al. Research advances in endometriosis-related signaling pathways: A review[J]. Biomed Pharmacother, 2023,164:114909. doi: 10.1016/j.biopha.2023.114909.
[17]	周奕含, 庞丽丽, 杨唯, 等. 基于Raf/MEK/ERK信号通路探讨内异康复片对hEM15A细胞的影响[J]. 中成药, 2024, 46(6):2062-2068. doi: 10.3969/j.issn.1001-1528.2024.06.049.
[18]	Shen Z, Zhao L, Yoo SA, et al. Emodin induces ferroptosis in colorectal cancer through NCOA4-mediated ferritinophagy and NF-κb pathway inactivation[J]. Apoptosis, 2024, 29(9/10):1810-1823. doi: 10.1007/s10495-024-01973-2.
[19]	刘一鸣, 刘志宏, 连方. 基于NCOA4/NF-κB信号通路介导的铁自噬探讨祛瘀解毒方对子宫内膜异位症模型大鼠子宫异位组织的影响[J]. 中医杂志, 2024, 65(6):627-635. doi: 10.13288/j.11-2166/r.2024.06.013.
[20]	李泉洋, 郝亚芳, 吴国泰, 等. PI3K/Akt信号通路调控子宫内膜异位症及中药干预作用研究进展[J]. 中国临床药理学与治疗学, 2024, 29(5):501-511. doi: 10.12092/j.issn.1009-2501.2024.05.004.
[21]	刘红丹, 金建祥, 姜迪, 等. 经方蠲痛饮对子宫内膜异位症作用和机制研究[J]. 中华中医药学刊, 2022, 40(4):246-250. doi: 10.13193/j.issn.1673-7717.2022.04.057.
[22]	Wang L, Wang W, Xu Y, et al. Low Levels of SPARC are Associated with Tumor Progression and Poor Prognosis in Human Endometrial Carcinoma[J]. Onco Targets Ther, 2020, 13:11549-11569. doi: 10.2147/OTT.S277795.
[23]	庄梦斐, 李盼盼, 丁楠, 等. 温经汤对大鼠子宫内膜异位症SPARC介导的上皮-间质转化的影响[J]. 上海中医药杂志, 2024, 58(4):9-18. doi: 10.16305/j.1007-1334.2024.2305026.
[24]	Zhang Z, Xiong Y, Jiang H, et al. Vaginal extracellular vesicles impair fertility in endometriosis by favoring Th17/Treg imbalance and inhibiting sperm activity[J]. J Cell Physiol, 2024, 239(4):e31188. doi: 10.1002/jcp.31188.
[25]	李雅静, 王旺, 毛洁, 等. 化瘀腹膜汤治疗子宫内膜异位症的疗效及对Th17/Treg相关炎症因子的调节作用[J]. 中药材, 2024,(4):1011-1015.
[26]	Fu K, Chen H, Mei L, et al. Berberine enhances autophagic flux by activating the Nrf2 signaling pathway in bovine endometrial epithelial cells to resist LPS-induced apoptosis[J]. Anim Sci J, 2023, 94(1):e13847. doi: 10.1111/asj.13847.
[27]	Warowicka A, Qasem B, Dera-Szymanowska A, et al. Effect of Protoberberine-Rich Fraction of Chelidonium majus L. on Endometriosis Regression[J]. Pharmaceutics, 2021, 13(7):931. doi: 10.3390/pharmaceutics13070931.
[28]	易华, 卢月, 陈剑坤, 等. 青藤碱对子宫内膜异位症大鼠异位组织TNF-α和NF-κB水平的影响[J]. 南方医科大学学报, 2010, 30(8):1874-1876. doi: 10.12122/j.issn.1673-4254.2010.08.031.
[29]	Ding J, Mei S, Wang K, et al. Curcumin modulates oxidative stress to inhibit pyroptosis and improve the inflammatory microenvironment to treat endometriosis[J]. Genes Dis, 2024, 11(3):101053. doi: 10.1016/ j.gendis.2023.06.022.
[30]	Zou W, Wang X, Xia X, et al. Resveratrol protected against the development of endometriosis by promoting ferroptosis through miR-21-3p/p53/SLC7A11 signaling pathway[J]. Biochem Biophys Res Commun, 2024,692:149338. doi: 10.1016/j.bbrc.2023.149338.
[31]	Chen X, Man G, Hung SW, et al. Therapeutic effects of green tea on endometriosis[J]. Crit Rev Food Sci Nutr, 2023, 63(18):3222-3235. doi: 10.1080/10408398.2021.1986465.
[32]	Jian X, Shi C, Luo W, et al. Therapeutic effects and molecular mechanisms of quercetin in gynecological disorders[J]. Biomed Pharmacother, 2024,173:116418. doi: 10.1016/j.biopha.2024.116418.
[33]	Woo JH, Jang DS, Choi JH. Luteolin Promotes Apoptosis of Endometriotic Cells and Inhibits the Alternative Activation of Endometriosis-Associated Macrophages[J]. Biomol Ther(Seoul), 2021, 29(6):678-684. doi: 10.4062/biomolther.2021.045.
[34]	Tassinari V, Smeriglio A, Stillittano V, et al. Endometriosis Treatment: Role of Natural Polyphenols as Anti-Inflammatory Agents[J]. Nutrients, 2023, 15(13):2967. doi: 10.3390/nu15132967.
[35]	Yi ZH, Li SQ, Ke JY, et al. Baicalein Relieves Ferroptosis-Mediated Phagocytosis Inhibition of Macrophages in Ovarian Endometriosis[J]. Curr Issues Mol Biol, 2022, 44(12):6189-6204. doi: 10.3390/cimb 44120422.
[36]	Meresman GF, Götte M, Laschke MW. Plants as source of new therapies for endometriosis: a review of preclinical and clinical studies[J]. Hum Reprod Update, 2021, 27(2):367-392. doi: 10.1093/ humupd/dmaa039. pmid: 33124671
[37]	Kabil SL, Rashed HE, Mohamed NM, et al. Parthenolide repressed endometriosis induced surgically in rats: Role of PTEN/PI3Kinase/AKT/GSK-3β/β-catenin signaling in inhibition of epithelial mesenchymal transition[J]. Life Sci, 2023,331:122037. doi: 10.1016/j.lfs.2023.122037.
[38]	Wu XH, Sun XL, Zhao C, et al. Exploring the pharmacological effects and potential targets of paeoniflorin on the endometriosis of cold coagulation and blood stasis model rats by ultra-performance liquid chromatography tandem mass spectrometry with a pattern recognition approach[J]. RSC Adv, 2019, 9(36):20796-20805. doi: 10.1039/c9ra03525g.
[39]	Cao Y, Ye Q, Zhuang M, et al. Ginsenoside Rg3 inhibits angiogenesis in a rat model of endometriosis through the VEGFR-2-mediated PI3K/Akt/mTOR signaling pathway[J]. PLoS One, 2017, 12(11):e0186520. doi: 10.1371/journal.pone.0186520.
[40]	Zhang Y, Huang O, Zhang W, et al. Astragaloside IV exerts anti-inflammatory role in endometriosis by downregulating TLR4/NF-κB pathway[J]. Trop J Pharm Res, 2019, 18(3):539-545. doi: 10.4314/tjpr.v18i3.14.
[41]	Zhang X, Li S, Chen Z, et al. Tanshinone ⅡA participates in the treatment of endometriosis by regulating adhesion, invasion, angiogenesis and inhibition of PI3K/Akt/mTOR signaling pathway[J]. Mol Med Rep, 2023, 28(5):221. doi: 10.3892/mmr.2023.13108.
[42]	Feng T, Wei S, Wang Y, et al. Rhein ameliorates adenomyosis by inhibiting NF-κB and β-Catenin signaling pathway[J]. Biomed Pharmacother, 2017, 94:231-237. doi: 10.1016/j.biopha.2017.07.089. pmid: 28763746